Last reviewed · How we verify
AV650
At a glance
| Generic name | AV650 |
|---|---|
| Sponsor | Avigen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis (PHASE2)
- Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury (PHASE2)
- AV650 Drug-Drug Interaction Study (PHASE1)
- Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AV650 CI brief — competitive landscape report
- AV650 updates RSS · CI watch RSS
- Avigen portfolio CI